Sign In

Login

Password

Forgot Password ? Sign Up

Nintedanib (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nintedanib" in Spanish language version.

refsWebsite
Global rank Spanish rank
12nih.gov
4th place
4th place
11doi.org
2nd place
2nd place
7issn.org
57th place
3rd place
3drugs.com
399th place
648th place
2boehringer-ingelheim.com
low place
low place
2clinicaltrials.gov
5,225th place
9,066th place
1web.archive.org
1st place
1st place
1avancesenrespiratorio.com
low place
low place
1archive.org
6th place
5th place
1ispch.cl
low place
low place
1europa.eu
68th place
91st place
1pmlive.com
low place
low place

archive.org

avancesenrespiratorio.com

boehringer-ingelheim.com

clinicaltrials.gov

  • ClinicalTrials.gov: BIBF 1120
  • Clinical trial number NCT01015118 for "LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer" at ClinicalTrials.gov

doi.org

dx.doi.org

  • Ahluwalia, N; Shea, BS; Tager, AM (15 de octubre de 2014). «New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.». American journal of respiratory and critical care medicine 190 (8): 867-78. PMID 25090037. doi:10.1164/rccm.201403-0509pp. 
  • Mazzei, ME; Richeldi, L; Collard, HR (junio de 2015). «Nintedanib in the treatment of idiopathic pulmonary fibrosis.». Therapeutic advances in respiratory disease 9 (3): 121-9. PMID 25862013. doi:10.1177/1753465815579365. 
  • Dimitroulis, IA (septiembre de 2014). «Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis». Respiratory care 59 (9): 1450-5. PMID 24782550. doi:10.4187/respcare.03023. 
  • Popat, S; Mellemgaard, A; Fahrbach, K; Martin, A; Rizzo, M; Kaiser, R; Griebsch, I; Reck, M (5 de diciembre de 2014). «Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis». Future oncology (London, England) 11 (3): 1-12. PMID 25478720. doi:10.2217/fon.14.290. 
  • Hilberg, F.; G. J. Roth, M. Krssak, S. Kautschitsch, W. Sommergruber, U. Tontsch-Grunt, P. Garin-Chesa, G. Bader, A. Zoephel, J. Quant, A. Heckel, W. J. Rettig (2008). «BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy». Cancer Res 68 (12): 4774-82. ISSN 1538-7445. PMID 18559524. doi:10.1158/0008-5472.CAN-07-6307. 
  • Okamoto, I.; H. Kaneda; T. Satoh; W. Okamoto; M. Miyazaki; R. Morinaga; S. Ueda; M. Terashima; A. Tsuya; A. Sarashina; K. Konishi; T. Arao; K. Nishio; R. Kaiser; K. Nakagawa (2010). «Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors». Mol Cancer Ther 9 (10): 2825-33. ISSN 1538-8514. PMID 20688946. doi:10.1158/1535-7163.MCT-10-0379. 
  • Mross, K.; M. Stefanic, D. Gmehling, A. Frost, F. Baas, C. Unger, R. Strecker, J. Henning, B. Gaschler-Markefski, P. Stopfer, L. de Rossi, R. Kaiser (2010). «Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors». Clin Cancer Res 16 (1): 311-9. ISSN 1078-0432. PMID 20028771. doi:10.1158/1078-0432.CCR-09-0694. 
  • Ellis, P. M.; R. Kaiser; Y. Zhao; P. Stopfer; S. Gyorffy; N. Hanna (2010). «Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients». Clin Cancer Res 16 (10): 2881-9. ISSN 1078-0432. PMID 20460487. doi:10.1158/1078-0432.CCR-09-2944. 
  • du Bois, A.; J. Huober; P. Stopfer; J. Pfisterer; P. Wimberger; S. Loibl; V. L. Reichardt; P. Harter (2010). «A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies». Ann Oncol 21 (2): 370-5. ISSN 1569-8041. PMID 19889612. doi:10.1093/annonc/mdp506. 
  • Selman, M; King, T. E.; Pardo, A; American Thoracic, Society; European Respiratory, Society; American College of Chest Physicians (2001). «Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy». Annals of internal medicine 134 (2): 136-51. PMID 11177318. doi:10.7326/0003-4819-134-2-200101160-00015. 
  • Wollin, L; Maillet, I; Quesniaux, V; Holweg, A; Ryffel, B (2014). «Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis». Journal of Pharmacology and Experimental Therapeutics 349 (2): 209-20. PMID 24556663. doi:10.1124/jpet.113.208223. 

drugs.com

europa.eu

ec.europa.eu

ispch.cl

issn.org

portal.issn.org

  • Hilberg, F.; G. J. Roth, M. Krssak, S. Kautschitsch, W. Sommergruber, U. Tontsch-Grunt, P. Garin-Chesa, G. Bader, A. Zoephel, J. Quant, A. Heckel, W. J. Rettig (2008). «BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy». Cancer Res 68 (12): 4774-82. ISSN 1538-7445. PMID 18559524. doi:10.1158/0008-5472.CAN-07-6307. 
  • Reck, M.; R. Kaiser; C. Eschbach; M. Stefanic; J. Love; U. Gatzemeier; P. Stopfer; J. von Pawel (2011). «A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer». Ann Oncol. ISSN 1569-8041. 
  • Okamoto, I.; H. Kaneda; T. Satoh; W. Okamoto; M. Miyazaki; R. Morinaga; S. Ueda; M. Terashima; A. Tsuya; A. Sarashina; K. Konishi; T. Arao; K. Nishio; R. Kaiser; K. Nakagawa (2010). «Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors». Mol Cancer Ther 9 (10): 2825-33. ISSN 1538-8514. PMID 20688946. doi:10.1158/1535-7163.MCT-10-0379. 
  • Mross, K.; M. Stefanic, D. Gmehling, A. Frost, F. Baas, C. Unger, R. Strecker, J. Henning, B. Gaschler-Markefski, P. Stopfer, L. de Rossi, R. Kaiser (2010). «Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors». Clin Cancer Res 16 (1): 311-9. ISSN 1078-0432. PMID 20028771. doi:10.1158/1078-0432.CCR-09-0694. 
  • Kropff, M.; J. Kienast; G. Bisping; W. E. Berdel; B. Gaschler-Markefski; P. Stopfer; M. Stefanic; G. Munzert (2009). «An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma». Anticancer Res 29 (10): 4233-8. ISSN 1791-7530. PMID 19846979. 
  • Ellis, P. M.; R. Kaiser; Y. Zhao; P. Stopfer; S. Gyorffy; N. Hanna (2010). «Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients». Clin Cancer Res 16 (10): 2881-9. ISSN 1078-0432. PMID 20460487. doi:10.1158/1078-0432.CCR-09-2944. 
  • du Bois, A.; J. Huober; P. Stopfer; J. Pfisterer; P. Wimberger; S. Loibl; V. L. Reichardt; P. Harter (2010). «A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies». Ann Oncol 21 (2): 370-5. ISSN 1569-8041. PMID 19889612. doi:10.1093/annonc/mdp506. 

nih.gov

ncbi.nlm.nih.gov

  • Ahluwalia, N; Shea, BS; Tager, AM (15 de octubre de 2014). «New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.». American journal of respiratory and critical care medicine 190 (8): 867-78. PMID 25090037. doi:10.1164/rccm.201403-0509pp. 
  • Mazzei, ME; Richeldi, L; Collard, HR (junio de 2015). «Nintedanib in the treatment of idiopathic pulmonary fibrosis.». Therapeutic advances in respiratory disease 9 (3): 121-9. PMID 25862013. doi:10.1177/1753465815579365. 
  • Dimitroulis, IA (septiembre de 2014). «Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis». Respiratory care 59 (9): 1450-5. PMID 24782550. doi:10.4187/respcare.03023. 
  • Popat, S; Mellemgaard, A; Fahrbach, K; Martin, A; Rizzo, M; Kaiser, R; Griebsch, I; Reck, M (5 de diciembre de 2014). «Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis». Future oncology (London, England) 11 (3): 1-12. PMID 25478720. doi:10.2217/fon.14.290. 
  • Hilberg, F.; G. J. Roth, M. Krssak, S. Kautschitsch, W. Sommergruber, U. Tontsch-Grunt, P. Garin-Chesa, G. Bader, A. Zoephel, J. Quant, A. Heckel, W. J. Rettig (2008). «BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy». Cancer Res 68 (12): 4774-82. ISSN 1538-7445. PMID 18559524. doi:10.1158/0008-5472.CAN-07-6307. 
  • Okamoto, I.; H. Kaneda; T. Satoh; W. Okamoto; M. Miyazaki; R. Morinaga; S. Ueda; M. Terashima; A. Tsuya; A. Sarashina; K. Konishi; T. Arao; K. Nishio; R. Kaiser; K. Nakagawa (2010). «Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors». Mol Cancer Ther 9 (10): 2825-33. ISSN 1538-8514. PMID 20688946. doi:10.1158/1535-7163.MCT-10-0379. 
  • Mross, K.; M. Stefanic, D. Gmehling, A. Frost, F. Baas, C. Unger, R. Strecker, J. Henning, B. Gaschler-Markefski, P. Stopfer, L. de Rossi, R. Kaiser (2010). «Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors». Clin Cancer Res 16 (1): 311-9. ISSN 1078-0432. PMID 20028771. doi:10.1158/1078-0432.CCR-09-0694. 
  • Kropff, M.; J. Kienast; G. Bisping; W. E. Berdel; B. Gaschler-Markefski; P. Stopfer; M. Stefanic; G. Munzert (2009). «An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma». Anticancer Res 29 (10): 4233-8. ISSN 1791-7530. PMID 19846979. 
  • Ellis, P. M.; R. Kaiser; Y. Zhao; P. Stopfer; S. Gyorffy; N. Hanna (2010). «Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients». Clin Cancer Res 16 (10): 2881-9. ISSN 1078-0432. PMID 20460487. doi:10.1158/1078-0432.CCR-09-2944. 
  • du Bois, A.; J. Huober; P. Stopfer; J. Pfisterer; P. Wimberger; S. Loibl; V. L. Reichardt; P. Harter (2010). «A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies». Ann Oncol 21 (2): 370-5. ISSN 1569-8041. PMID 19889612. doi:10.1093/annonc/mdp506. 
  • Selman, M; King, T. E.; Pardo, A; American Thoracic, Society; European Respiratory, Society; American College of Chest Physicians (2001). «Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy». Annals of internal medicine 134 (2): 136-51. PMID 11177318. doi:10.7326/0003-4819-134-2-200101160-00015. 
  • Wollin, L; Maillet, I; Quesniaux, V; Holweg, A; Ryffel, B (2014). «Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis». Journal of Pharmacology and Experimental Therapeutics 349 (2): 209-20. PMID 24556663. doi:10.1124/jpet.113.208223. 

pmlive.com

web.archive.org